Literature DB >> 2824608

Purification and partial biochemical characterization of a human monocyte-derived, neutrophil-activating peptide that lacks interleukin 1 activity.

J M Schröder1, U Mrowietz, E Morita, E Christophers.   

Abstract

A novel monocyte-derived neutrophil-activating peptide (MONAP) produced by lipopolysaccharide- and phorbol myristate acetate-stimulated human peripheral blood monocytes was purified by sequential ion exchange-high performance liquid chromatography (HPLC), size exclusion HPLC, and reversed phase HPLC. Biologic activities of the purified cytokine were monitored by either an enzyme release assay or a chemotaxis assay, using peripheral human neutrophils. Purified MONAP was found to be homogeneous, giving a single peak on size-exclusion HPLC, reversed-phase HPLC, as well as a single 10-kDa band on silver-stained polyacrylamide gels. Purified MONAP stimulate human neutrophil chemotaxis at an estimated molarity of 5 x 10(-11) M. Half-maximal enzyme release of cytochalasin B pretreated neutrophils occurred at 2 to 3 x 10(-10) M, whereas superoxide anion production elicited by various concentrations of MONAP was found to be low. Isolated human peripheral monocytes, as well as human eosinophils, showed no chemotactic response to MONAP, indicating neutrophil specificity. MONAP activity was separated from thymocyte-stimulating activity by reversed-phase HPLC, indicating nonidentity with interleukin (IL)-1. This was further supported by heat resistance of MONAP, which is in contrast to the heat sensitivity of IL-1. In addition, IL-1 obtained as a by-product during isolation of MONAP did not stimulate human neutrophil chemotaxis.

Entities:  

Mesh:

Substances:

Year:  1987        PMID: 2824608

Source DB:  PubMed          Journal:  J Immunol        ISSN: 0022-1767            Impact factor:   5.422


  119 in total

1.  Isolation and purification of chemokines from natural sources.

Authors:  J M Schröder
Journal:  Mol Biotechnol       Date:  2001-05       Impact factor: 2.695

2.  Impaired interleukin-8-induced degranulation of polymorphonuclear neutrophils from human immunodeficiency virus type 1-infected individuals.

Authors:  S Meddows-Taylor; D J Martin; C T Tiemessen
Journal:  Clin Diagn Lab Immunol       Date:  1999-05

3.  The role of CD18 in IL-8 induced dermal and synovial inflammation.

Authors:  M J Forrest; G J Eiermann; R Meurer; L A Walakovits; D E MacIntyre
Journal:  Br J Pharmacol       Date:  1992-06       Impact factor: 8.739

4.  Exposure to in utero lipopolysaccharide induces inflammation in the fetal ovine skin.

Authors:  Matthew W Kemp; Masatoshi Saito; Ilias Nitsos; Alan H Jobe; Suhas G Kallapur; John P Newnham
Journal:  Reprod Sci       Date:  2010-10-05       Impact factor: 3.060

Review 5.  The Role of Chemokines in Fibrotic Wound Healing.

Authors:  Jie Ding; Edward E Tredget
Journal:  Adv Wound Care (New Rochelle)       Date:  2015-11-01       Impact factor: 4.730

6.  Identification and characterization of macrophage inflammatory protein 2.

Authors:  S D Wolpe; B Sherry; D Juers; G Davatelis; R W Yurt; A Cerami
Journal:  Proc Natl Acad Sci U S A       Date:  1989-01       Impact factor: 11.205

7.  Inflammatory mediators in dengue virus infection in children: interleukin-8 and its relationship to neutrophil degranulation.

Authors:  M Juffrie; G M van Der Meer; C E Hack; K Haasnoot; A J Veerman; L G Thijs
Journal:  Infect Immun       Date:  2000-02       Impact factor: 3.441

8.  Milk-derived antimicrobial peptides to protect against Neonatal Diarrheal Disease: An alternative to antibiotics.

Authors:  Heather L Wilson; Rachelle M Buchanan; Brenda Allan; Suresh K Tikoo
Journal:  Procedia Vaccinol       Date:  2012-05-02

9.  Transient rise in serum interleukin-8 concentration during acute myocardial infarction.

Authors:  Y Abe; M Kawakami; M Kuroki; T Yamamoto; M Fujii; H Kobayashi; T Yaginuma; A Kashii; M Saito; K Matsushima
Journal:  Br Heart J       Date:  1993-08

10.  Methylprednisolone inhibits increase of interleukin 8 and 6 during open heart surgery.

Authors:  T Kawamura; K Inada; H Okada; K Okada; R Wakusawa
Journal:  Can J Anaesth       Date:  1995-05       Impact factor: 5.063

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.